All In MedTech

Device Trial Radar · NCT07214545

External Trigeminal Nerve Stimulation for Children With ASD + ADHD to Reduce Elevated Symptoms

Phase IIa Clinical Trial of External Trigeminal Nerve Stimulation for Autistic Children With Attention Deficit/Hyperactivity Disorder

Last checked: Nov 19, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Oct 6, 2025

Primary completion

Sep 2027

Study completion Jan 31, 2028

Sponsor

Lead sponsor
University of California, San FranciscoAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Oct 9, 2025

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 7 years, up to 14 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn if external trigeminal nerve stimulation (eTNS) works to treat ADHD symptoms in children on the autism spectrum (ASD). It will also learn about the efficacy and tolerability of the eTNS device. The main questions it aims to answer are: * Does eTNS reduce ADHD symptoms? * Does eTNS improve core and associated features of ASD? Participation spans 8-12 weeks and includes: * 4-5 in-person visits * 4 brief virtual check-ins * Nightly use of the eTNS device with a small sticky patch applied to child's forehead * Randomized assignment (those who start with the sham device may try the active device later)

Conditions

  • Attention Deficit Disorder With Hyperactivity (ADHD)
  • Autism Spectrum Disorder (ASD)

Interventions

  • Trigeminal Nerve StimulationDevice

    This intervention is expected to have an effect following a treatment period of 6 weeks.

  • Sham Trigeminal Nerve StimulationDevice

    This intervention is NOT expected to have an effect following a treatment period of 6 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in ADHD SymptomsTime frame: Baseline to end of treatment at 6 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • UCSF Nancy Friend Pritzker Psychiatry Building

    San Francisco, California · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.